Current Location:Home > Industry Information

Industry Information

Date of publication:2020/7/24 17:19:09
Liraglutide, sold under the brand name Victoza, is a medication used to treat diabetes mellitus type 2 and obesity. Liraglutide causes a glucose-dependent increase in insulin secretion, decreases glucagon secretion and promotes weight loss by inhibiting appetite. Liraglutide probably induces satiety through activation of different areas in the hind brain and possibly by preserving free leptin levels. 
Type 2 diabetes, formerly known as adult-onset diabetes, is a form of diabetes which is characterized by high blood sugar, insulin resistance and relative lack of insulin. Common symptoms include increased thirst, frequent urination and unexplained weight loss.
Type 2 diabetes has a different pathophysiology and etiology as compared to type 1 diabetes. There are many new factors exist. For example, the increased prevalence of obesity among all age groups and both sex physical inactivity, poor diet, and urbanization – means that the number of patients diagnosed with type 2 diabetes is rising. 
Overweight and obesity are defined by an excess accumulation of adipose tissue to an extent that impairs both physical and psychosocial health and well-being. People are generally considered obese when their body mass index (BMI), is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight. Obesity increases the various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, certain types of cancer, osteoarthritis, depression, and so on.

Both type 2 diabetes and obesity are associated with insulin resistance. Most obese individuals, despite being insulin resistant, do not develop hyperglycemia. 
Liraglutide for weight management: a critical review of the evidence from onlinelibrary.wiley.com

The FDA drug liraglutide has been shown to help obese patients lose weight by suppressing their appetite. However, where and how the drug acts in the brain was not fully understood, until now. A new preclinical study from the Perelman School of Medicine at the University of Pennsylvania, published in Science Translational Medicine on Mar 4, 2020, shows how liraglutide crosses the brain's blood barrier to engage with a region of the brainstem known as the nucleus tractus solitarius (NTS), which is responsible for balancing food intake and energy expenditure.
Liraglutide interacts with targets called glucagon-like peptide-1 receptors (GLP-1R) in various parts of the brain to suppress hunger. This is the first study to show how a distinct group of neurons that express GLP-1Rs within the NTS of the brainstem play a key role in mediating these effects.
"This finding opens up the door for future obesity drug treatments that could be used in conjunction with this FDA-approved therapy to treat obesity," said senior author Matthew R. Hayes, PhD, an associate professor of Psychiatry at Penn.
Liraglutide was first approved by the FDA in 2010 to improve blood sugar levels in patients with type 2 diabetes. In late 2014, the FDA approved the drug to treat obesity after several clinical trials showed that patients on the drug lost an average of 8 percent of their body weight compared to those not on the drug. Today, five FDA-approved obesity drugs are available, but researchers are working to develop more, as the United States continues to battle rising rates of obesity. Nearly 70 percent of Americans are considered overweight or obese, according to the Centers for Disease Control and Prevention.
Liraglutide mimics a hormone known as GLP-1, which controls the amount of glucose in the body and helps regulate feeding behavior. The drug works by resisting enzymatic degradation and by activating the necessary GLP-1 receptors within the brain to help reduce a person's appetite, subsequently producing weight loss.
Hunan Huateng Pharmaceutical Co., Ltd. is a leading pharmaceutical company focusing on R&D of pharmaceutical intermediates. We can provide antidiabetic drugs intermediates such as liraglutide intermediates and semaglutide intermediates for your research. For liraglutide intermediates, they are CAS No. 536721-25-2, CAS No. 294855-91-7, CAS No. 1491158-62-3 and CAS No. 204521-63-1. We can make scale-up production with capacities varying from gram to kilograms and multi tons.

Related articles:

[1] The things you need to know about diabetes
[2] Novo Nordisk's Semaglutide Shows Promise in Weight Loss
[3] Oral Peptide Therapeutics: Advances and Challenges
[4] Antidiabetic Drugs Classification and Mechanism of Action

[1] Newly discovered brain response to obesity drug may inform future treatments
[2] Liraglutide can help adolescents with obesity manage their weight